Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05519670 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Study acronym: CAPRICE
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study will be to combine oral capecitabine and oral niraparib such thz association may increase clinical benefits of PARP inhibitors in germline BRCA mutated HER2 negative advanced breast cancer patients.
Trial Details
NCT Number NCT05519670
Lead Sponsor Institut Paoli-Calmettes
Collaborators: GlaxoSmithKline
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov